Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects
In a double-blind, randomised, placebo-controlled crossover study in 30 healthy males, a single 125 mg dose of MDMA given after conditioning enhanced rapid fear extinction and retention as indexed by reduced skin conductance responses to the conditioned stimulus, but had no effect on fear‑potentiated startle. MDMA raised plasma oxytocin levels and produced subjective effects linked to reduced CS+/CS− discrimination, though oxytocin itself did not predict extinction outcomes, suggesting MDMA may facilitate certain forms of learned fear attenuation relevant to its therapeutic use.
Authors
- Patrick Vizeli
- Matthias Liechti
- Nikhil Varghese
Published
Abstract
Background
3,4-Methylenedioxymethamphetamine (MDMA) has shown initial promise as an adjunct in psychotherapy to treat posttraumatic stress disorder (PTSD). Its efficacy and safety have been demonstrated across phase I–III studies. However, the mechanism underlying the potential utility of MDMA to treat PTSD in humans has not yet been thoroughly investigated. Preliminary evidence suggests that MDMA may facilitate fear extinction recall, which may be through the release of oxytocin. To test this hypothesis, we examined the efficacy of acute MDMA treatment to enhance fear extinction learning and recall.
Methods
We used a two-period, double-blind, randomized, placebo-controlled crossover design in 30 healthy male subjects who received a placebo and a single dose of MDMA (125 mg). Fear extinction was tested using two separate Pavlovian fear conditioning paradigms, one using skin conductance response (SCR), and the other fear-potentiated startle (FPS) to conditioned cues. MDMA treatment occurred after fear conditioning and 2 h before extinction learning. Extinction recall was tested 23 h after MDMA intake. Additional outcome measures included subjective effects, emotion recognition tasks, plasma levels of oxytocin, and pharmacokinetics.
Results
Fear conditioning and extinction learning were successful in both fear extinction paradigms (generalized eta–squared [ges] for SCR: 0.08; FPS: 0.07). Compared to placebo treatment, MDMA treatment significantly reduced SCRs to the reinforced conditioned stimulus (CS+) during extinction learning (ges = 0.03) and recall (ges = 0.06). Intensity of the subjective effects of MDMA (good effect, trust, and openness) during extinction learning negatively correlated with the discrimination between CS+ and the safety stimulus (CS−) during recall. MDMA did not influence FPS to conditioned cues. Oxytocin concentration was increased fourfold on average by MDMA during acute effects but was not associated with fear extinction outcomes.
Conclusions
MDMA treatment facilitated rapid fear extinction and retention of extinction as measured by SCR to fear cues, in line with animal studies of MDMA facilitation of extinction. However, this effect may be limited to certain forms of learned fear responses, as it was not observed in the extinction model using startle reactivity as the outcome. This study provides further evidence for the facilitation of extinction with MDMA treatment and suggests this may be a component of its efficacy when paired with psychotherapy.Clinical
Research Summary of 'Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects'
Introduction
MDMA is being investigated as an adjunct to psychotherapy for PTSD and social anxiety because it produces prosocial and anxiolytic subjective effects and alters emotion processing. Earlier research in animals and a small number of human studies suggested that MDMA may facilitate fear extinction or otherwise alter fear-memory processes, and oxytocin release has been proposed as one possible mediating mechanism. However, findings have been mixed across species and paradigms, and the mechanistic basis of MDMA's putative benefit in exposure-based therapies remains uncertain. Vizeli and colleagues set out to test whether a single acute MDMA dose enhances fear extinction learning and recall in healthy volunteers, and whether peripheral oxytocin release, MDMA plasma levels, or subjective effects predict any such enhancement. The investigators used two established human Pavlovian conditioning paradigms that index learned fear by skin conductance response (SCR) and by fear‑potentiated startle (FPS), employing a double‑blind, placebo‑controlled, crossover design with a 125 mg MDMA dose administered after acquisition and 2 h before extinction learning; extinction recall was tested the next day about 23 h after dosing.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Vizeli, P., Straumann, I., Duthaler, U., Varghese, N., Eckert, A., Paulus, M. P., Risbrough, V., & Liechti, M. E. (2022). Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.906639
References (27)
Papers cited by this study that are also in Blossom
Bershad, A. K., Mayo, L. M., Van Hedger, K. et al. · Neuropsychopharmacology (2019)
Carhart-Harris, R. L., Murphy, K., Leech, R. et al. · Biological Psychiatry (2015)
Curry, D. W., Young, M. B., Tran, A. N. et al. · Neuropharmacology (2017)
Danforth, A. L., Struble, C., Yazar-Klosinski, B. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Dolder, P. C., Müller, F., Schmid, Y. et al. · Psychopharmacology (2017)
Dumont, G., Sweep, F., van der Steen, R. et al. · Social Neuroscience (2009)
Feduccia, A. A., Mithoefer, M. C. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Feduccia, A. A., Jerome, L., Mithoefer, M. C. et al. · Psychopharmacology (2020)
Holze, F., Vizeli, P., Müller, F. et al. · Neuropsychopharmacology (2019)
Holze, F., Avedisian, I., Varghese, N. et al. · Frontiers in Pharmacology (2021)
Show all 27 referencesShow fewer
Hysek, C. M., Vollenweider, F. X., Liechti, M. E. · BMJ Open (2010)
Hysek, C. M., Fink, A., Simmler, L. D. et al. · Journal of Clinical Psychopharmacology (2013)
´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Kirkpatrick, M. G., Lee, R., Wardle, M. C. et al. · Neuropsychopharmacology (2014)
Liechti, M. E., Baumann, C., Gamma, A. et al. · Neuropsychopharmacology (2000)
Maples-Keller, J. L., Norrholm, S. D., Burton, M. et al. · Journal of Psychopharmacology (2022)
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2010)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2012)
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)
Studerus, E., Vizeli, P., Harder, S. et al. · Journal of Psychopharmacology (2021)
Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)
Vizeli, P., Liechti, M. E. · PLOS ONE (2018)
Young, M. B., Andero, R., Ressler, K. J. et al. · Translational Psychiatry (2015)
Young, M. B., Norrholm, S. D., Khoury, L. M. et al. · Psychopharmacology (2017)
Cited By (11)
Papers in Blossom that reference this study
Ramaekers, J. G., Kuypers, K. P. C., Vollenweider, F. X. · Molecular Psychiatry (2026)
Sevchik, B. L., Singleton, S. P., Lahey, A. et al. · MedRvix (2026)
Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)
Straumann, I., Vizeli, P., Avedisian, I. et al. · Neuropsychopharmacology (2025)
Atila, C., Straumann, I., Vizeli, P. et al. · JAMA Network Open (2024)
Bershad, A. K., Hsu, D. T., De Wit, H. · Journal of Psychopharmacology (2024)
Mitchell, J., Ot’alora G, M., van der Kolk, B. et al. · Nature Medicine (2023)
Sarmanlu, M., Kuypers, K. P. C., Vizeli, P. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023)
Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)
Kangaslampi, S., Zijlmans, J. · European Child and Adolescent Psychiatry (2023)
Show all 11 papersShow fewer
Singleton, S. P., Wang, J. B., Mithoefer, A. T. et al. · Frontiers in Psychiatry (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.